Kevin Conroy is the Chief Executive Officer, President, and Chairman of the Board of Exact Sciences. He became CEO 11 years ago and he has been part of a team that transformed Exact Sciences into one of the world’s premier cancer diagnostics companies with more than 4,500 employees.
Mr. Conroy has led Exact Sciences through the development, clinical trial, regulatory approval, and commercialization of its noninvasive colorectal cancer screening test, Cologuard®. This culminated with Cologuard becoming the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Since 2014, millions of Americans have used Cologuard to screen for colorectal cancer, the second leading cause of cancer death in the United States.
In 2019, Exact Sciences’ acquisition of Genomic Health, Inc., united two of the industry’s strongest brands, Cologuard and Oncotype DX®, and established the company’s position as the global leader in advanced cancer diagnostics. The global company is working to improve screening, early detection, and treatment guidance throughout the cancer continuum.
Before joining Exact Sciences, Mr. Conroy served as CEO and President of Third Wave Technologies, a molecular diagnostics company that developed a breakthrough cervical cancer screening test before being acquired by Hologic in 2008. Mr. Conroy also held leadership positions at GE Healthcare, a global leader in medical imaging and information technology, and practiced intellectual property law in private practice. Mr. Conroy currently serves as a director of Epizyme, Inc. and Adaptive Biotechnology Corporation.
Mr. Conroy is active in the Wisconsin community. He serves as a director of the Greater Madison Chamber of Commerce and on the University of Wisconsin-Madison Chancellor’s Advisory Council. He has also served as chair of The United Way of Dane County’s 2016 annual campaign and as a board member of Overture Center for the Arts.
A native of Flint, Michigan, Mr. Conroy holds a Bachelor of Science degree in electrical engineering from Michigan State University and earned his Juris Doctorate from the University of Michigan Law School.
What is Kevin T. Conroy's net worth?
The estimated net worth of Kevin T. Conroy is at least $66.27 million as of November 13th, 2024. Mr. Conroy owns 1,074,191 shares of Exact Sciences stock worth more than $66,266,843 as of December 2nd. This net worth estimate does not reflect any other investments that Mr. Conroy may own. Additionally, Mr. Conroy receives a salary of $3,140,000.00 as CEO at Exact Sciences. Learn More about Kevin T. Conroy's net worth.
How old is Kevin T. Conroy?
What is Kevin T. Conroy's salary?
How do I contact Kevin T. Conroy?
Has Kevin T. Conroy been buying or selling shares of Exact Sciences?
Over the course of the past ninety days, Kevin T. Conroy has bought $1,001,325.00 in shares of Exact Sciences stock. Most recently, on Wednesday, November 13th, Kevin T. Conroy bought 19,500 shares of Exact Sciences stock. The stock was acquired at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares of the company's stock, valued at $55,159,707.85. Learn More on Kevin T. Conroy's trading history.
Who are Exact Sciences' active insiders?
Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.
Are insiders buying or selling shares of Exact Sciences?
In the last twelve months, Exact Sciences insiders bought shares 1 times. They purchased a total of 19,500 shares worth more than $1,001,325.00. In the last twelve months, insiders at the medical research company sold shares 36 times. They sold a total of 77,348 shares worth more than $4,737,043.93. The most recent insider tranaction occured on November, 13th when CEO Kevin T Conroy bought 19,500 shares worth more than $1,001,325.00. Insiders at Exact Sciences own 1.4% of the company.
Learn More about insider trades at Exact Sciences. Information on this page was last updated on 11/13/2024.